Technical Analysis for RGNX - REGENXBIO Inc.

Grade Last Price % Change Price Change
C 22.33 0.63% 0.14
RGNX closed up 0.63 percent on Monday, March 18, 2024, on 62 percent of normal volume.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 0.63%
MACD Bearish Signal Line Cross Bearish 2.20%
Wide Bands Range Expansion 2.20%
Calm After Storm Range Contraction -0.62%
Inside Day Range Contraction -0.62%
Wide Bands Range Expansion -0.62%
Calm After Storm Range Contraction 1.59%
Wide Bands Range Expansion 1.59%
1,2,3 Pullback Bullish Bullish Swing Setup -2.28%

   Recent Intraday Alerts

Alert Time
Up 1% about 16 hours ago
60 Minute Opening Range Breakout about 19 hours ago
Down 3% about 22 hours ago
Fell Below Previous Day's Low about 22 hours ago
Down 2 % about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

REGENXBIO Inc. Description

REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Emerging Technologies Molecular Biology Gene Therapy Genetics Medical Genetics Macular Degeneration Applied Genetics Cholesterol Gene Delivery Wet Age Related Macular Degeneration Lipoprotein Hypercholesterolemia Retinitis Adeno Associated Virus Mucopolysaccharidosis Retinitis Pigmentosa Homozygous Familial Hypercholesterolemia Iduronidase Rgx

Is RGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 28.8
52 Week Low 11.83
Average Volume 838,717
200-Day Moving Average 17.87
50-Day Moving Average 17.13
20-Day Moving Average 20.95
10-Day Moving Average 22.83
Average True Range 1.81
RSI (14) 60.16
ADX 41.69
+DI 27.21
-DI 13.99
Chandelier Exit (Long, 3 ATRs) 23.36
Chandelier Exit (Short, 3 ATRs) 22.36
Upper Bollinger Bands 25.34
Lower Bollinger Band 16.56
Percent B (%b) 0.66
BandWidth 41.89
MACD Line 1.54
MACD Signal Line 1.66
MACD Histogram -0.1143
Fundamentals Value
Market Cap 982.34 Million
Num Shares 44 Million
EPS -5.99
Price-to-Earnings (P/E) Ratio -3.73
Price-to-Sales 7.86
Price-to-Book 1.97
PEG Ratio 0.26
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.37
Resistance 3 (R3) 24.24 23.42 24.03
Resistance 2 (R2) 23.42 22.90 23.49 23.92
Resistance 1 (R1) 22.88 22.58 23.15 23.01 23.80
Pivot Point 22.06 22.06 22.20 22.13 22.06
Support 1 (S1) 21.52 21.54 21.79 21.65 20.86
Support 2 (S2) 20.70 21.22 20.77 20.74
Support 3 (S3) 20.16 20.70 20.63
Support 4 (S4) 20.29